Other than in the adjunctive use for delivery by cesarean section, Transderm Scop should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus. Because scopolamine is excreted in human milk, caution should be exercised when Transderm Scop is administered to a nursing woman. Labor and Delivery Scopolamine administered parenterally at higher doses than the dose delivered by Transderm Scop does not increase the duration of labor, nor does it affect uterine contractions. Scopolamine does cross the placenta. The safety and effectiveness of Transderm Scop in children has not been established.
Children are particularly susceptible to the side effects of belladonna alkaloids.
Transderm Scop should not be used in children because it is not known whether this system will release an amount of scopolamine that could produce serious adverse effects in children. The adverse reactions for Transderm Scop are provided separately for patients with motion sickness and with post-operative nausea and vomiting. This occurred in about two thirds of patients on drug. A less frequent adverse drug reaction was drowsiness, which occurred in less than one sixth of patients on drug. Transient impairment of eye accommodation, including blurred vision and dilation of the pupils, was also observed.